All > Mindfulness

Intravenous Ketamine for Major Depressive Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Major Depressive DisorderIntravenous Ketamine - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether mindfulness training enhances the effects of ketamine for depression.

Eligible Conditions
  • Major Depressive Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
ketamine infusion
1
Intravenous Ketamine
1
Ketamine-assisted psychotherapy

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: infusion +40min

30 days post-intervention
Daily Spiritual Experience Scale
Mindful Attention Awareness Scale
Montgomery-Asberg Depression Rating Scale
Quick Inventory of Depressive Symptoms
modified Hamilton Depression Rating Scale
80min post-infusion
State Mindfulness Scale
Day 1
Dual probe video task
Sustained Attention Response Task (SART) omission errors
Sustained Attention Response Task (SART) self-reported task focus
infusion +40min
Hood Mysticism Scale
infusion +80min
Awe Experience Scale

Trial Safety

Safety Progress

1 of 3

Similar Trials

2
ketamine infusion
1
Intravenous Ketamine
2
Ketamine-assisted psychotherapy

Trial Design

2 Treatment Groups

Intravenous Ketamine + Academic Exercises
1 of 2
Intravenous Ketamine + Mindfulness Exercises
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Intravenous Ketamine · No Placebo Group · Phase 1 & 2

Intravenous Ketamine + Mindfulness ExercisesExperimental Group · 2 Interventions: Intravenous Ketamine, Brief Mindfulness Exercises · Intervention Types: Drug, Behavioral
Intravenous Ketamine + Academic ExercisesActiveComparator Group · 2 Interventions: Intravenous Ketamine, Academic Exercises · Intervention Types: Drug, Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: infusion +40min

Who is running the clinical trial?

Rebecca PriceLead Sponsor
5 Previous Clinical Trials
590 Total Patients Enrolled
Rebecca Price, PhDPrincipal InvestigatorUniversity of Pittsburgh

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are between the ages of 18 and 65 years.
You have a score of 14 or higher on the Hamilton Depression Rating Scale (modified Ham-D).

Who else is applying?

What state do they live in?
North Carolina50.0%
Louisiana50.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Western Psychiatric Institute and Clinic100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top